This content is from: Patents

Generics say French Eli Lilly decision not worth its salt

European in-house counsel say the ‘dangerous’ ruling will delay the launch of generic products and create legal uncertainty

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial